| Hazard Information | Back Directory | [Uses]
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research[1]. | [in vivo]
Tibulizumab (LY 3090106; 660 μg/mouse, i.p; 66 μg/mouse, s.c) effectively antagonizes the biological effects induced by human BAFF and IL-17 in the mouse[1].
In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life[1].
| [IC 50]
IL-17A: 14 pM (Kd); BAFF: 60 pM (Kd) | [References]
[1] Robert J Benschop, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019 Aug/Sep;11(6):1175-1190. DOI:10.1080/19420862.2019.1624463 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|